2′-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2′-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites

Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study

(2011) Hind T. Hatoum et al.   CURRENT MEDICAL RESEARCH AND OPINION

Hypomethylating agents for urologic cancers

(2011) Ajjai S Alva et al.   Future Oncology

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Global Reactivation of Epigenetically Silenced Genes in Prostate Cancer

(2010) I. Ibragimova et al.   Cancer Prevention Research

5-azacytidine treatment reorganizes genomic histone modification patterns

(2010) Vitalina M. Komashko et al.   Epigenetics

Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass Spectrometry

(2009) Daniel K. Rogstad et al.   CHEMICAL RESEARCH IN TOXICOLOGY